Related Experiment Video
Updated: Feb 11, 2026

Treatment Model for Young Patients with Psychogenic Erectile Dysfunction and Resultant Infertility
Published on: May 30, 2025
[Imatinib as Second-Line Treatment Drug for CML Patients Intolerant to Nilotinib]
Jing Qi1, You-Hai Xu1, He-Sheng He1
1Department of Hematology,Yijishan Hospital,Wannan Medical College,Wuhu 241001,Anhui Province,China.
Objective:
To explore the individualized treatment for patient with chronic phase chronic myeloid leukemia(CML-CP).
Methods:
The clinical data and treatment process of one CML-CP patient which intolerated to nilotinib were analyzed.
Results:
Nilotinib was given to the patient once the diagnosis of CML-CP was set. Although major molecular remission (MMR) and complete cytogenetic remission (CCyR) were obtained during treatment for 3 months, a grade 3-4 hepatotoxicity appeared in the course of treatment.With drug reduction and symptomatic treatment, nilotinib was discontinued after 3 withdrawals and replaced with imatinib in January 11, 2015. The patients achieved MMR and CCyR at 7 months after imatinib replacement. At present, the patient tolerated well without any adverse events.
Conclusion:
Imatinib can be used as a second-line treatment drug for CML patients who was intolerant to nilotinib, and with less adverts, good effect and so on.
More Related Videos
07:42Patient-Derived Tumor Explants As a "Live" Preclinical Platform for Predicting Drug Resistance in Patients
Published on: February 7, 2021
08:32Studying the Hypothalamic Insulin Signal to Peripheral Glucose Intolerance with a Continuous Drug Infusion System into the Mouse Brain
Published on: January 4, 2018
Related Concept Videos
Drug Dosing: Geriatric Patients
Drug Dosing: Obese Patients
Drugs for Treatment of Constipation-Predominant IBS
Drugs for Treatment of Ulcerative Colitis in IBD
Drugs for Treatment of Diarrhea-Predominant IBS
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Pharmacokinetics in Pediatric Patients: Drug Excretion